JP Morgan Chase
CMTA

JP Morgan Chase’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

JP Morgan Chase’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,597,795
Closed -$41.7M – 6186
2019
Q1 		$41.7M Buy
1,597,795
+118,915
+8% +$2.22M 0.01% 1048
2018
Q4 		$17.4M Buy
1,478,880
+441,833
+43% +$5.5M ﹤0.01% 1581
2018
Q3 		$11.6M Buy
1,037,047
+155,336
+18% +$1.63M ﹤0.01% 2073
2018
Q2 		$11.6M Buy
881,711
+136,842
+18% +$2.22M ﹤0.01% 2018
2018
Q1 		$11.3M Buy
744,869
+38,572
+5% +$628K ﹤0.01% 1939
2017
Q4 		$13.4M Buy
706,297
+52,575
+8% +$880K ﹤0.01% 1887
2017
Q3 		$10.9M Buy
+653,722
New +$10.7M ﹤0.01% 1918

JP Morgan Chase's CMTA Position: Q2 2019 in Review

JP Morgan Chase sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2019, closing a stake of 1,597,795 shares — an estimated $41.7M sold.

JP Morgan Chase first reported a position in CMTA in Q3 2017 and held it in 7 quarters. The position peaked at $41.7M in Q1 2019. 0 funds tracked by Wall St. Rank hold CMTA as of Q2 2019.

  • JP Morgan Chase reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
  • JP Morgan Chase sold 1,597,795 Clementia Pharmaceuticals Inc. shares in Q2 2019, an estimated $41.7M.
  • JP Morgan Chase first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 7 quarters.
  • JP Morgan Chase's Clementia Pharmaceuticals Inc. position peaked at $41.7M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2019.

Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.